DARE - Dare Bioscience Debt to Book Capitalization Ratio

Graphic logo of Dare Bioscience (DARE)

Dare Bioscience, Inc. (DARE) proprietary centers in the US are creating unique therapies for women in underserved niches. This chart on GURU.Markets showing total debt to book capitalization captures the dynamics of liabilities, where the 0.00 mark reflects the latest data. Revenue growth will be driven by the launch of XACIATO and new contraceptives, while the absence of geopolitical barriers guarantees the stability of research.

DARE (Daré Bioscience, Inc.) Debt to Book Value history from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for Dare Bioscience (DARE)

- price and consensus price forecast:
Stock Price Dare Bioscience, Inc.|DARE - Analyst Consensus Forecast
- market capitalization data:
Market Value Daré Bioscience, Inc.|DARE - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Daré Bioscience|DARE - Company Net Assets|Market Capitalization to Book Value Ratio darebioscience.com|DARE - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Dare Bioscience, Inc.|DARE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Dare Bioscience Inc.|DARE - Company Total Debt|Debt to Book Capitalization Ratio Daré Bioscience, Inc.
Summary company analytics:Dare Bioscience, Inc. - DARE
Core merchandise of Daré Bioscience, Inc.

The ratio is calculated as total liabilities divided by the book value of equity. This metric determines the business's resilience to credit risks and the probability of bankruptcy during macroeconomic downturns. For Dare Bioscience, Inc. (DARE), it is critically important to minimize debt to ensure that the advancement of women's health depends on clinical success rather than the cost of borrowing. By analyzing the debt-to-equity ratio, an investor assesses the pace of liability reduction. This chart confirms the financial autonomy of the company.

Who Dare Bioscience, Inc. competes with

Debts to Book Capitalization OGN (Organon & Co.)|TherapeuticsMD Inc - Debts to Book Capitalization|Debt to Book Capitalization Ratio Palatin Technologies, Inc. (PTN)